Lung Cancer Clinical Trial

Biology of Young Lung Cancer Study: The YOUNG LUNG Study

Summary

The purpose of this research study is to learn more about lung cancer (NSCLC or SCLC) diagnosed in adults at ages 45 or younger.

View Full Description

Full Description

This research study looks to enroll as many people diagnosed with lung cancer at 45 years old or younger in order to:

Better understand causes of lung cancer in individuals 45 years old and younger, which is a rare disease
Better estimate lung cancer risks and potential risk factors for lung cancer in individuals 45 years old and younger
Examine tumor (somatic) or normal (germline) genetic changes that may be shared among young lung cancer patients
Improve opportunities for screening and treatment of lung cancer in individuals 45 years old and younger

Study procedures will include:

Collecting information from participants' medical record and two (2) short questionnaires
Collecting blood and/or saliva samples
Collecting tumor tissue samples (optional)

It is expected that about 500 people will take part in this research study. Participants will be in this study until it closes or the participant withdraws consent.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Age 45 and under at lung cancer diagnosis
Pathologically confirmed bronchogenic lung carcinoma (NSCLC or SCLC of any stage) at any treatment time point
Provision of written informed consent
Willingness to undergo no more than two (2) peripheral blood draws in a four (4) week period, with no more than 50 ml peripheral blood collected over eight (8) weeks
Individuals under age 18 are eligible for study if they meet defined criteria; in addition, consent for participation must be given by a legal guardian or parent

Exclusion Criteria:

Individuals who decline to sign consent
Individuals who are unable to give consent or assent and are without a designated healthcare proxy
Compromise of patient diagnosis or staging if tissue is used for research

Study is for people with:

Lung Cancer

Estimated Enrollment:

500

Study ID:

NCT05265429

Recruitment Status:

Not yet recruiting

Sponsor:

Dana-Farber Cancer Institute

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 2 Locations for this study

See Locations Near You

Massachusetts General Hospital
Boston Massachusetts, 02114, United States More Info
Jessica Line, MD
Contact
617-724-1134
[email protected]
Jessica Lin, MD
Principal Investigator
Beth Israel Deaconess Medical Center
Boston Massachusetts, 02115, United States More Info
Daniel Costa, MD PhD
Contact
617-667-9236
Daniel Costa, MD PhD
Principal Investigator
Brigham and Women's Hospital
Boston Massachusetts, 02115, United States More Info
Pasi A Janne, MD, PhD
Contact
617-632-6036
[email protected]
Pasi A Janne, MD, PhD
Principal Investigator
Dana-Farber Cancer Institute
Boston Massachusetts, 02115, United States More Info
Pasi A Janne, MD, PhD
Contact
617-632-6036
[email protected]
Pasi A Janne, MD, PhD
Principal Investigator

How clear is this clinincal trial information?

Study is for people with:

Lung Cancer

Estimated Enrollment:

500

Study ID:

NCT05265429

Recruitment Status:

Not yet recruiting

Sponsor:


Dana-Farber Cancer Institute

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.